Establishment of tumor‐specific copy number alterations from plasma DNA of patients with cancer

Abstract

With the increasing number of available predictive biomarkers, clinical management of cancer is becoming increasingly reliant on the accurate serial monitoring of tumor genotypes. We tested whether tumor‐specific copy number changes can be inferred from the peripheral blood of patients with cancer. To this end, we determined the plasma DNA size distribution and the fraction of mutated plasma DNA fragments with deep sequencing and an ultrasensitive mutation‐detection method, i.e., the Beads, Emulsion, Amplification, and Magnetics (BEAMing) assay. When analyzing the plasma DNA of 32 patients with Stage IV colorectal carcinoma, we found that a subset of the patients (34.4%) had a biphasic size distribution of plasma DNA fragments that was associated with increased circulating tumor cell numbers and elevated concentration of mutated plasma DNA fragments. In these cases, we were able to establish genome‐wide tumor‐specific copy number alterations directly from plasma DNA. Thus, we could analyze the current copy number status of the tumor genome, which was in some cases many years after diagnosis of the primary tumor. An unexpected finding was that not all patients with progressive metastatic disease appear to release tumor DNA into the circulation in measurable quantities. When we analyzed plasma DNA from 35 patients with metastatic breast cancer, we made similar observations suggesting that our approach may be applicable to a variety of tumor entities. This is the first description of such a biphasic distribution in a surprisingly high proportion of cancer patients which may have important implications for tumor diagnosis and monitoring.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 35

1. 1.

   Walther A, Johnstone E, Swanton C, et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009;9:489-99.

   Not in our library10.1038/nrc2645

2. 2.

   Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646-50.

   Not in our library

3. 3.

   Stroun M, Anker P, Maurice P, et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 1989;46:318-22.

   Not in our library10.1159/000226740

4. 4.

   Pinzani P, Salvianti F, Zaccara S, et al. Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations. Clin Chim Acta. 2010;412:2141-5.

   Not in our library10.1016/j.cca.2011.07.027

5. 5.

   Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11:426-37.

   Not in our library10.1038/nrc3066

6. 6.

   Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer. 2002;2:210-9.

   Not in our library10.1038/nrc755

7. 7.

   van der Vaart M, Pretorius PJ. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated? Clin Biochem. 2010;43:26-36.

   Not in our library10.1016/j.clinbiochem.2009.08.027

8. 8.

   Muller I, Beeger C, Alix-Panabieres C, et al. Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: potential and technical improvements. Clin Chem. 2008;54:688-96.

   Not in our library10.1373/clinchem.2007.099333

9. 9.

   Schwarzenbach H, Alix-Panabieres C, Muller I, et al. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res. 2009;15:1032-8.

   Not in our library10.1158/1078-0432.ccr-08-1910

10. 10.

    Begum S, Brait M, Dasgupta S, et al. An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin Cancer Res. 2011;17:4494-503.

    Not in our library10.1158/1078-0432.ccr-10-3436

11. 11.

    Gormally E, Caboux E, Vineis P, et al. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res. 2007;635:105-17.

    Not in our library10.1016/j.mrrev.2006.11.002

12. 12.

    Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA. 2005;102:16368-73.

    Not in our library10.1073/pnas.0507904102

13. 13.

    Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985-90.

    Not in our library10.1038/nm.1789

14. 14.

    Diehl F, Schmidt K, Durkee KH, et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology. 2008;135:489-98.

    Not in our library10.1053/j.gastro.2008.05.039

15. 15.

    Leary RJ, Kinde I, Diehl F, et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med. 2010;2:20ra14.

    Not in our library10.1126/scitranslmed.3000702

16. 16.

    McBride DJ, Orpana AK, Sotiriou C, et al. Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Gene Chromosome Cancer. 2010;49:1062-9.

    Not in our library10.1002/gcc.20815

17. 17.

    Nawroz H, Koch W, Anker P, et al. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med. 1996;2:1035-7.

    Not in our library10.1038/nm0996-1035

18. 18.

    Yung TK, Chan KC, Mok TS, et al. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res. 2009;15:2076-84.

    Not in our library10.1158/1078-0432.ccr-08-2622

19. 19.

    Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532-6.

    Not in our library10.1038/nature11156

20. 20.

    Diaz LA, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486:537-40.

    Not in our library10.1038/nature11219

21. 21.

    Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4:136ra68.

    Not in our library10.1126/scitranslmed.3003726

22. 22.

    Dhallan R, Au WC, Mattagajasingh S, et al. Methods to increase the percentage of free fetal DNA recovered from the maternal circulation. JAMA. 2004;291:1114-9.

    Not in our library10.1001/jama.291.9.1114

23. 23.

    Lo YM, Chan KC, Sun H, et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med. 2010;2:61ra91.

    Not in our library10.1126/scitranslmed.3001720

24. 24.

    Riethdorf S, Fritsche H, Muller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007;13:920-8.

    Not in our library10.1158/1078-0432.ccr-06-1695

25. 25.

    Diehl F, Li M, He Y, et al. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods. 2006;3:551-9.

    Not in our library10.1038/nmeth898

26. 26.

    Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011;3:111ra21.

    Not in our library10.1126/scitranslmed.3003161

27. 27.

    Bignell GR, Greenman CD, Davies H, et al. Signatures of mutation and selection in the cancer genome. Nature. 2010;463:893-8.

    Not in our library10.1038/nature08768

28. 28.

    Kan Z, Jaiswal BS, Stinson J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466:869-73.

    Not in our library10.1038/nature09208

29. 29.

    Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61:1659-65.

    Not in our library

30. 30.

    Pinzani P, Salvianti F, Pazzagli M, et al. Circulating nucleic acids in cancer and pregnancy. Methods. 2010;50:302-7.

    Not in our library10.1016/j.ymeth.2010.02.004

31. 31.

    Umetani N, Kim J, Hiramatsu S, et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem. 2006;52:1062-9.

    Not in our library10.1373/clinchem.2006.068577

32. 32.

    Wang BG, Huang HY, Chen YC, et al. Increased plasma DNA integrity in cancer patients. Cancer Res. 2003;63:3966-8.

    Not in our library

33. 33.

    Chan KC, Jiang P, Zheng YW, et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem. 2013;59:211-24.

    Not in our library10.1373/clinchem.2012.196014

34. 34.

    Leary RJ, Sausen M, Kinde I, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med. 2012;4:162ra54.

    Not in our library10.1126/scitranslmed.3004742

35. 35.

    Lo YM, Zhang J, Leung TN, et al. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet. 1999;64:218-24.

    Not in our library10.1086/302205

Cited by papers we hold 8

• Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden · 2021
  No notice
• Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management · 2018
  No notice
• CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA · 2017
  No notice
• The potential of liquid biopsies for the early detection of cancer · 2017
  No notice
• Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma · 2015
  No notice
• Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing · 2014
  No notice
• Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing · 2013
  No notice
• The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients · 2013
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.